Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Spark Therapeutics (ONCE) PT Lowered to $46 at BMO Capital
February 19, 2019 3:38 PM ESTBMO Capital analyst Matthew Luchini lowered the price target on Spark Therapeutics (NASDAQ: ONCE) to $46.00 (from $48.00) while maintaining a Market Perform rating following results.
... More